Ticagrelor Versus Prasugrel in Acute Coronary Syndrome: Real-World Treatment and Safety
<b>Introduction</b>: A direct head-to-head comparison between potent P2Y12 inhibitors: prasugrel versus ticagrelor is still lacking. <b>Purpose</b>: In this single-center study, we sought to address the efficacy and safety of these two third-generation antiplatelet drugs, aft...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-05-01
|
| Series: | Medicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2305-6320/12/2/13 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850168412027748352 |
|---|---|
| author | Fadel Bahouth Boris Chutko Haitham Sholy Sabreen Hassanain Gassan Zaid Evgeny Radzishevsky Ibrahem Fahmwai Mahmod Hamoud Nemer Samnia Johad Khoury Idit Dobrecky-Mery |
| author_facet | Fadel Bahouth Boris Chutko Haitham Sholy Sabreen Hassanain Gassan Zaid Evgeny Radzishevsky Ibrahem Fahmwai Mahmod Hamoud Nemer Samnia Johad Khoury Idit Dobrecky-Mery |
| author_sort | Fadel Bahouth |
| collection | DOAJ |
| description | <b>Introduction</b>: A direct head-to-head comparison between potent P2Y12 inhibitors: prasugrel versus ticagrelor is still lacking. <b>Purpose</b>: In this single-center study, we sought to address the efficacy and safety of these two third-generation antiplatelet drugs, after about a decade of practical use. <b>Methods</b>: A retrospective observational study included all patients who were admitted with acute coronary syndrome between January 2010 and December 2019 and were discharged with aspirin and either prasugrel or ticagrelor after percutaneous coronary intervention. Patients were divided into two groups based on the dual antiplatelet drugs prescribed. Primary endpoint: A composite endpoint of cardiovascular death, recurrent coronary syndrome, or ischemic stroke at one year. Secondary endpoint: Significant bleeding according to the BARC classification (types 3, 4, or 5). <b>Results</b>: During this period, 746 patients met the inclusion criteria. The primary endpoint was reached in 70 patients (9.4%): 24 patients (8.0%) in the group treated with ticagrelor and 46 patients (10.3%) in the group treated with prasugrel (<i>p</i>-value = 0.303). In terms of safety events, significant bleeding was not statistically different between the ticagrelor and prasugrel groups: 13 (2.9%) vs. 9 (3%), respectively (<i>p</i>-value = 0.9). More patients discontinued their treatment before the end of the year among those treated with ticagrelor compared to those treated with prasugrel (16.7% vs. 9.6%, <i>p</i>-value = 0.003). <b>Conclusions</b>: There was no significant difference in the occurrence of recurrent cardiac events, stroke, or cardiovascular death, nor significant bleeding among ACS patients treated either with prasugrel or ticagrelor. |
| format | Article |
| id | doaj-art-c3ec0675b9ce414a9c57bf27023fc40c |
| institution | OA Journals |
| issn | 2305-6320 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Medicines |
| spelling | doaj-art-c3ec0675b9ce414a9c57bf27023fc40c2025-08-20T02:20:58ZengMDPI AGMedicines2305-63202025-05-011221310.3390/medicines12020013Ticagrelor Versus Prasugrel in Acute Coronary Syndrome: Real-World Treatment and SafetyFadel Bahouth0Boris Chutko1Haitham Sholy2Sabreen Hassanain3Gassan Zaid4Evgeny Radzishevsky5Ibrahem Fahmwai6Mahmod Hamoud7Nemer Samnia8Johad Khoury9Idit Dobrecky-Mery10Department of Cardiology, Bnai-Zion Medical Center, Haifa 31096, IsraelDepartment of Cardiology, Bnai-Zion Medical Center, Haifa 31096, IsraelDepartment of Cardiology, Bnai-Zion Medical Center, Haifa 31096, IsraelDepartment of Cardiology, Bnai-Zion Medical Center, Haifa 31096, IsraelDepartment of Cardiology, Bnai-Zion Medical Center, Haifa 31096, IsraelDepartment of Cardiology, Bnai-Zion Medical Center, Haifa 31096, IsraelDepartment of Cardiology, Bnai-Zion Medical Center, Haifa 31096, IsraelDepartment of Cardiology, Bnai-Zion Medical Center, Haifa 31096, IsraelDepartment of Cardiology, Bnai-Zion Medical Center, Haifa 31096, IsraelPulmonology Division, Carmel Medical Center, Haifa 3436212, IsraelDepartment of Cardiology, Bnai-Zion Medical Center, Haifa 31096, Israel<b>Introduction</b>: A direct head-to-head comparison between potent P2Y12 inhibitors: prasugrel versus ticagrelor is still lacking. <b>Purpose</b>: In this single-center study, we sought to address the efficacy and safety of these two third-generation antiplatelet drugs, after about a decade of practical use. <b>Methods</b>: A retrospective observational study included all patients who were admitted with acute coronary syndrome between January 2010 and December 2019 and were discharged with aspirin and either prasugrel or ticagrelor after percutaneous coronary intervention. Patients were divided into two groups based on the dual antiplatelet drugs prescribed. Primary endpoint: A composite endpoint of cardiovascular death, recurrent coronary syndrome, or ischemic stroke at one year. Secondary endpoint: Significant bleeding according to the BARC classification (types 3, 4, or 5). <b>Results</b>: During this period, 746 patients met the inclusion criteria. The primary endpoint was reached in 70 patients (9.4%): 24 patients (8.0%) in the group treated with ticagrelor and 46 patients (10.3%) in the group treated with prasugrel (<i>p</i>-value = 0.303). In terms of safety events, significant bleeding was not statistically different between the ticagrelor and prasugrel groups: 13 (2.9%) vs. 9 (3%), respectively (<i>p</i>-value = 0.9). More patients discontinued their treatment before the end of the year among those treated with ticagrelor compared to those treated with prasugrel (16.7% vs. 9.6%, <i>p</i>-value = 0.003). <b>Conclusions</b>: There was no significant difference in the occurrence of recurrent cardiac events, stroke, or cardiovascular death, nor significant bleeding among ACS patients treated either with prasugrel or ticagrelor.https://www.mdpi.com/2305-6320/12/2/13acute coronary syndrometicagrelorprasugreldual anti platelet drugs |
| spellingShingle | Fadel Bahouth Boris Chutko Haitham Sholy Sabreen Hassanain Gassan Zaid Evgeny Radzishevsky Ibrahem Fahmwai Mahmod Hamoud Nemer Samnia Johad Khoury Idit Dobrecky-Mery Ticagrelor Versus Prasugrel in Acute Coronary Syndrome: Real-World Treatment and Safety Medicines acute coronary syndrome ticagrelor prasugrel dual anti platelet drugs |
| title | Ticagrelor Versus Prasugrel in Acute Coronary Syndrome: Real-World Treatment and Safety |
| title_full | Ticagrelor Versus Prasugrel in Acute Coronary Syndrome: Real-World Treatment and Safety |
| title_fullStr | Ticagrelor Versus Prasugrel in Acute Coronary Syndrome: Real-World Treatment and Safety |
| title_full_unstemmed | Ticagrelor Versus Prasugrel in Acute Coronary Syndrome: Real-World Treatment and Safety |
| title_short | Ticagrelor Versus Prasugrel in Acute Coronary Syndrome: Real-World Treatment and Safety |
| title_sort | ticagrelor versus prasugrel in acute coronary syndrome real world treatment and safety |
| topic | acute coronary syndrome ticagrelor prasugrel dual anti platelet drugs |
| url | https://www.mdpi.com/2305-6320/12/2/13 |
| work_keys_str_mv | AT fadelbahouth ticagrelorversusprasugrelinacutecoronarysyndromerealworldtreatmentandsafety AT borischutko ticagrelorversusprasugrelinacutecoronarysyndromerealworldtreatmentandsafety AT haithamsholy ticagrelorversusprasugrelinacutecoronarysyndromerealworldtreatmentandsafety AT sabreenhassanain ticagrelorversusprasugrelinacutecoronarysyndromerealworldtreatmentandsafety AT gassanzaid ticagrelorversusprasugrelinacutecoronarysyndromerealworldtreatmentandsafety AT evgenyradzishevsky ticagrelorversusprasugrelinacutecoronarysyndromerealworldtreatmentandsafety AT ibrahemfahmwai ticagrelorversusprasugrelinacutecoronarysyndromerealworldtreatmentandsafety AT mahmodhamoud ticagrelorversusprasugrelinacutecoronarysyndromerealworldtreatmentandsafety AT nemersamnia ticagrelorversusprasugrelinacutecoronarysyndromerealworldtreatmentandsafety AT johadkhoury ticagrelorversusprasugrelinacutecoronarysyndromerealworldtreatmentandsafety AT iditdobreckymery ticagrelorversusprasugrelinacutecoronarysyndromerealworldtreatmentandsafety |